New July FDA approvals and updates span multiple therapeutic areas, ranging from rare metabolic disorders to eczema. Approvals include oral Ekterly for hereditary angioedema (HAE), topical Anzupgo for chronic hand eczema, and Zegfrovy tablet for non-small cell lung cancers. Regeneron’s Lynozyfic has received accelerated approval for multiple myeloma, Kirsty is an interchangeable biosimilar to NovoLog, and Sephience gains a green light in rare phenylketonuria. Other label updates include notable changes for Skytrofa, Doptelet, Kisunla and Empaveli.